Source: Virtual Congress 2020 – Chronic cough: only symptom or disease?
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. Nussbaum (South San Francisco, United States of America), J. Mccrea (West Point, United States of America), A. Hussain (West Point, United States of America), R. Evers (Rahway, United States of America), B. Ma (West Point, United States of America), J. Laabs (Lincoln, United States of America), C. Rillera (Las Vegas, United States of America), G. Garrett (Boston, United States of America), Y. Li (Rahway, United States of America), M. Vallee (West Point, United States of America), D. Panebianco (North Wales, United States of America), S. Stoch (Rahway, United States of America), M. Iwamoto (Rahway, United States of America). Gefapixant does not have meaningful drug interactions with a MATE1/2K inhibitor or an OATP1B substrate. 4565

Member's Comments

No comment yet.

Related content which might interest you: Pharmacological properties of a novel PI3Kd inhibitor, DS-1515 Source: International Congress 2018 – Basic pharmacology Year: 2018 In vitro pharmacological characterization of the potent, lung selective pan-JAK inhibitor TD-8236 Source: International Congress 2019 – Advances in asthma pharmacology Year: 2019 In vitro and in vivo pharmacological profile of RP6503, a novel dual PI3K Δ/gamma inhibitor, in pulmonary disease systems Source: Annual Congress 2013 –Emerging new targets for the treatment of respiratory diseases Year: 2013 Roflumilast N-oxide, a selective PDE4 inhibitor, curbs platelet-leukocyte interactions Source: Annual Congress 2011 - Translational models of disease Year: 2011 Identification of mechanism-specific biomarkers to guide development of the lung-selective inhaled pan-JAK inhibitor TD-8236 Source: Virtual Congress 2020 – Asthma science: novel targets and mechanisms Year: 2020 NIK-626; a dual inhibitor of thromboxane synthase and 5-lipoxygenase, potential candidate as a novel anti-asthma compound Source: Eur Respir J 2001; 18: Suppl. 33, 264s Year: 2001 ADME properties of a novel PI3Kd inhibitor, DS-1515, in preclinical studies Source: International Congress 2018 – Basic pharmacology Year: 2018 Effect of CYP3A4 inhibitors verapamil and itraconazole on the pharmacokinetics of AZD7986, an oral DPP1 inhibitor Source: International Congress 2017 – Asthma management Year: 2017 In vivo pharmacological profile of PKF242-484 and PKF241-466, novel dual inhibitors of TNF-α converting enzyme and matrix metalloproteinases, in models of airway inflammation Source: Eur Respir J 2002; 20: Suppl. 38, 169s Year: 2002 Molecular and cellular profile of the structurally novel phosphodiesterase (PDE) 4 inhibitor, BAY 19-8004 Source: Eur Respir J 2001; 18: Suppl. 33, 36s Year: 2001 Human alpha-1 proteinase inhibitor (tal6004) manufacturing process and pathogen safety Source: Annual Congress 2009 - Treatment of airways disease Year: 2009 Pirfenidone, proton pump inhibitor, N acetyl cysteine (PINPOINT) therapy for IPF: Tolerance and safety profile among Indian patients Source: Annual Congress 2012 - Diffuse parenchymal lung disease III Year: 2012 Nonclinical safety profiles of DS-1515, a novel oral PI3Kd inhibitor. Source: International Congress 2018 – Basic pharmacology Year: 2018 Smoking has no effect on the pharmacokinetics of roflumilast, a new, orally active, selective PDE4 inhibitor Source: Eur Respir J 2001; 18: Suppl. 33, 156s Year: 2001 Roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, is effective in the treatment of asthma Source: Eur Respir J 2002; 20: Suppl. 38, 303s Year: 2002 Late-breaking abstract: Pre-clinical characterization of RP3128, a novel and potent CRAC channel inhibitor for the treatment of respiratory disorders Source: Annual Congress 2011 - Late-Breaking Abstracts Session: New treatments and targets for airway disease Year: 2011 NIK-616, a new type of selective phosphodiesteraseIV(PDE IV) inhibitor with reduced emetic activity Source: Eur Respir J 2001; 18: Suppl. 33, 35s Year: 2001 In vitro pharmacological characterization of CHF6001, a novel selective phosphodiesterase 4 (PDE4) inhibitor with a robust anti-inflammatory profile Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014 PI3K inhibitor add-on strategy improve glucocorticoid insensitivity in severe asthma Source: Virtual Congress 2020 – Asthma science: novel targets and mechanisms Year: 2020 NIK-616,a new type of selective PDE IV inhibitor with reduced emetic activity Source: Eur Respir J 2002; 20: Suppl. 38, 618s Year: 2002